While further studies are needed to confirm these benefits in larger lupus populations, the research opens the door to new possibilities
In my case, my abs at 44 are way worthier of a tube top than my abs at 24
We don't yet have long-term data in otherwise healthy individuals, and these medications were not designed or studied for longevity per se." That view reflects the scientific consensus in the field: the early findings are genuinely promising and warrant further investigation, but they do not yet support prescribing GLP-1 drugs to healthy, non-obese, non-diabetic people for the purpose of slowing aging
FDA isnt just watching mild enzyme bumps, theyre demanding full Hys Law level tracking, case level reporting, and discontinuations tied to liver signals
This increased competition and focus on affordability could lead to greater accessibility and better treatment options for individuals struggling with obesity